Published in Blood on February 27, 2008
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood (2011) 2.22
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol (2013) 1.57
Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol (2012) 1.56
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol (2008) 1.51
Transcriptional data: a new gateway to drug repositioning? Drug Discov Today (2012) 1.40
Independent component analysis: mining microarray data for fundamental human gene expression modules. J Biomed Inform (2010) 1.39
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell (2012) 1.24
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood (2015) 1.14
Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res (2013) 1.10
Content-based microarray search using differential expression profiles. BMC Bioinformatics (2010) 1.07
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer (2010) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett (2010) 1.04
Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res (2009) 1.01
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 1.00
ProfileChaser: searching microarray repositories based on genome-wide patterns of differential expression. Bioinformatics (2011) 0.99
Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) (2010) 0.96
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant (2010) 0.95
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia (2010) 0.95
Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci U S A (2013) 0.92
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program (2013) 0.91
Natural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugs. PLoS One (2010) 0.90
Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. ACS Chem Biol (2010) 0.90
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. Mol Pain (2010) 0.89
Systems analysis of high-throughput data. Adv Exp Med Biol (2014) 0.87
Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Lett (2012) 0.86
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther (2014) 0.84
Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors. Cell Death Differ (2012) 0.83
Can we finally target the leukemic stem cells? Best Pract Res Clin Haematol (2008) 0.82
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem (2016) 0.81
Why doesn't imatinib cure chronic myeloid leukemia? Oncologist (2010) 0.80
Genetic and proteomic approaches to identify cancer drug targets. Br J Cancer (2011) 0.79
Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene (2012) 0.79
Cancer chemoprevention by traditional chinese herbal medicine and dietary phytochemicals: targeting nrf2-mediated oxidative stress/anti-inflammatory responses, epigenetics, and cancer stem cells. J Tradit Complement Med (2013) 0.79
IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates. CPT Pharmacometrics Syst Pharmacol (2015) 0.78
Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. PLoS One (2012) 0.78
Celastrol regulates multiple nuclear transcription factors belonging to HSP90's clients in a dose- and cell type-dependent way. Cell Stress Chaperones (2010) 0.78
Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. Biomed Res Int (2014) 0.78
Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. J Hematol Oncol (2016) 0.78
An integrated network platform for contextual prioritization of drugs and pathways. Mol Biosyst (2015) 0.77
Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig (2014) 0.77
Application of biclustering of gene expression data and gene set enrichment analysis methods to identify potentially disease causing nanomaterials. Beilstein J Nanotechnol (2015) 0.76
Targeting LSCs: powering an old tool. Blood (2008) 0.76
Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery. Pharmacogenomics J (2016) 0.76
Parthenolide Induces Apoptosis in Committed Progenitor AML Cell line U937 via Reduction in Osteopontin. Rep Biochem Mol Biol (2016) 0.75
In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. Expert Opin Drug Discov (2016) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Identifying biological themes within lists of genes with EASE. Genome Biol (2003) 31.72
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res (2005) 17.58
Gene selection and classification of microarray data using random forest. BMC Bioinformatics (2006) 12.45
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Cancer stem cells. N Engl J Med (2006) 9.63
PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics (2005) 8.41
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem (1999) 4.77
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
Submission of microarray data to public repositories. PLoS Biol (2004) 3.83
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A (2002) 3.12
The effects of normalization on the correlation structure of microarray data. BMC Bioinformatics (2005) 2.87
Inference of a genetic network by a combined approach of cluster analysis and graphical Gaussian modeling. Bioinformatics (2002) 2.13
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol (2003) 2.00
Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res (2000) 1.94
Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol (2006) 1.91
Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest (2006) 1.91
Microarray databases: standards and ontologies. Nat Genet (2002) 1.86
Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2001) 1.70
Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene (2004) 1.58
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood (2007) 1.52
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics (2002) 1.37
Hemin induces an iron-dependent, oxidative injury to human neuron-like cells. J Neurosci Res (2003) 1.24
Considerations for targeting malignant stem cells in leukemia. Cancer Control (2004) 1.20
Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem (2003) 1.20
4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis. J Biol Chem (1999) 1.12
4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic Biol Med (2007) 1.03
Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. J Surg Res (2004) 1.02
Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep (2007) 0.98
Feverfew: weeding out the root of leukaemia. Expert Opin Biol Ther (2005) 0.96
The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res Mol Brain Res (2000) 0.95
Heme arginate pretreatment attenuates pulmonary NF-kappaB and AP-1 activation induced by hemorrhagic shock via heme oxygenase-1 induction. Med Chem (2006) 0.93
Inhibition of allergen-induced eosinophil recruitment by natural tetranortriterpenoids is mediated by the suppression of IL-5, CCL11/eotaxin and NFkappaB activation. Int Immunopharmacol (2005) 0.89
Proteasome inactivation upon aging and on oxidation-effect of HSP 90. Mol Biol Rep (1997) 0.89
4-hydroxynonenal and TGF-beta1 concur in inducing antiproliferative effects on the CaCo-2 human colon adenocarcinoma cell line. Biofactors (2005) 0.86
Heme oxygenase-1 induction and dependent increase in ferritin. A protective antioxidant stratagem in hemin-treated rat brain. Dev Neurosci (2002) 0.85
Differential sensitivity to 4-hydroxynonenal for normal and malignant mesenchymal cells. Redox Rep (2007) 0.83
The cathedulin alkaloids. Bull Narc (1980) 0.80
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Cancer stem cells. N Engl J Med (2006) 9.63
The increasing complexity of the cancer stem cell paradigm. Science (2009) 5.45
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Nonsense-mediated mRNA decay in mammalian cells involves decapping, deadenylating, and exonucleolytic activities. Mol Cell (2003) 4.17
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature (2010) 3.20
Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A (2002) 3.12
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood (2003) 2.93
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell (2013) 2.92
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood (2005) 2.79
Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett (2009) 2.77
The exon junction complex is detected on CBP80-bound but not eIF4E-bound mRNA in mammalian cells: dynamics of mRNP remodeling. EMBO J (2002) 2.76
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell (2013) 2.51
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood (2007) 2.34
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood (2008) 2.34
Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood (2011) 2.27
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program (2004) 2.23
Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci U S A (2002) 2.15
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet (2005) 2.11
The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell (2004) 2.09
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol (2003) 2.00
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood (2010) 1.92
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol (2007) 1.89
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant (2011) 1.88
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood (2008) 1.88
A histone acetyltransferase regulates active DNA demethylation in Arabidopsis. Science (2012) 1.78
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell (2006) 1.76
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma (2006) 1.67
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood (2005) 1.63
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene (2004) 1.58
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood (2007) 1.52
Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood (2004) 1.49
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol (2008) 1.49
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res (2008) 1.48
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood (2008) 1.42
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biol Ther (2010) 1.40
Melampomagnolide B: a new antileukemic sesquiterpene. Bioorg Med Chem (2011) 1.40
Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res (2002) 1.39
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci (2009) 1.36
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov (2012) 1.33
NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res (2002) 1.30
Wind-dragged corolla enhances self-pollination: a new mechanism of delayed self-pollination. Ann Bot (2007) 1.25
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell (2012) 1.24
A common genetic mechanism in malignant bone marrow diseases. N Engl J Med (2009) 1.23
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone (2006) 1.23
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell (2004) 1.22
Considerations for targeting malignant stem cells in leukemia. Cancer Control (2004) 1.20
In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood (2009) 1.18
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer (2012) 1.16
Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol (2005) 1.16
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res (2007) 1.16
Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant (2010) 1.15
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2011) 1.14
Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A (2014) 1.12
Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectin. Biotechnol Bioeng (2009) 1.11
Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn (2003) 1.10
Leukemia stem cells in 2010: current understanding and future directions. Blood Rev (2011) 1.09
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest (2013) 1.08